Rapport Therapeutics, Inc. (RAPP)
NASDAQ: RAPP · Real-Time Price · USD
29.50
+0.80 (2.79%)
Dec 5, 2025, 4:00 PM EST - Market closed
Rapport Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Rapport Therapeutics stock have an average target of 46.6, with a low estimate of 28 and a high estimate of 80. The average target predicts an increase of 57.97% from the current stock price of 29.50.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Rapport Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 3 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Initiates $47 | Strong Buy | Initiates | $47 | +59.32% | Nov 19, 2025 |
| Citizens | Citizens | Buy Maintains $77 → $80 | Buy | Maintains | $77 → $80 | +171.19% | Nov 7, 2025 |
| Truist Securities | Truist Securities | Strong Buy Initiates $44 | Strong Buy | Initiates | $44 | +49.15% | Sep 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $31 → $34 | Strong Buy | Maintains | $31 → $34 | +15.25% | Sep 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $31 | Strong Buy | Initiates | $31 | +5.08% | Aug 6, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.89
from -3.78
EPS Next Year
-3.61
from -2.89
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.82 | -2.55 | ||||
| Avg | -2.89 | -3.61 | ||||
| Low | -2.94 | -4.19 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.